Referred TestsAdvancing the
diagnosis.
Testing for the full spectrum of hematologic disorders.
Our comprehensive test menu has been
created to aid in diagnosis and treatment
selection across the full spectrum of hematologic
disorders. Through our clinical experience, we
have developed and validated practice-based,
data-driven algorithms that improve patient care, increase efficiency, and reduce costs.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly hematology testing newsletter.
Results That Matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
1 million
hematology and hematopathology tests performed annually
70+
hematologists and hematopathologists on staff at Mayo Clinic
31
hematology-focused algorithms to guide test ordering
24/7
support from Mayo Clinic physicians and scientists
Innovation and collaboration between experts
Our laboratories are led by board-certified hematopathologists who focus on molecular diagnostics and prognostics of hematologic disorders, reviewing cases to provide interpretation of results related to clinically relevant genes. These experts are on call 24/7, so they are available any time you need answers.
The right test
at the right time
More than 30 hematology-focused algorithms are integrated directly into our testing approaches to ensure the right tests are being ordered at the right time. This approach simplifies the ordering process, arriving at clinically actionable answers for your patients, faster.
Unparalleled service
Our testing is supported by a round-the-clock staff of expert laboratory directors and genetic counselors, who assist with everything from test ordering to results interpretation. Our experts collaborate closely with clients, not only to reach the right answers for current patients, but also to guide the development of future testing.
A Case-Based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis
Using test-ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and the literature, we will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.
The Latest
Xinjie Xu, Ph.D., co-director of Mayo's Genetics and Genomics Laboratory, explains Mayo Clinic Laboratories' updated approach to testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as multiple myeloma. Based on recently published data, the new testing algorithms focus on use of fluorescence in situ hybridization (FISH) panels, rather than chromosome studies.
The Mayo Clinic Laboratories' national symposium A Case-Based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis can now be viewed online.
In this month’s “Hot Topic,” James Hoyer, M.D., discusses the importance of using a control tube during osmotic fragility testing.
Nahla Heikal, M.D., co-director of Mayo Clinic's Special Coagulation Laboratory, addresses the connection between COVID-19 and coagulopathy.
On Dec. 4, Mayo Clinic Laboratories will host the Friday Satellite Symposium A Case-Based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis, preceding the 62nd American Society of Hematology Annual Meeting and Exposition.